Axatilimab (SNDX-6352)
Chronic Graft-versus-Host Disease (cGVHD)
Key Facts
About Syndax Pharmaceuticals
Syndax Pharmaceuticals is a clinical-stage biotech focused on developing novel inhibitors for cancers with high unmet need, primarily through its menin and BET inhibitor platforms. Its lead asset, revumenib, is a potential best-in-class menin inhibitor in late-stage development for KMT2A-rearranged and NPM1-mutant acute leukemias. The company's strategy leverages deep mechanistic insight to target key drivers of oncogenesis and fibrosis, aiming to deliver transformative therapies. With a disciplined approach to clinical development and a strong cash position, Syndax is advancing a targeted pipeline toward key regulatory milestones.
View full company profileAbout Syndax Pharmaceuticals
Syndax Pharmaceuticals is a clinical-stage biotech focused on developing novel inhibitors for cancers with high unmet need, primarily through its menin and BET inhibitor platforms. Its lead asset, revumenib, is a potential best-in-class menin inhibitor in late-stage development for KMT2A-rearranged and NPM1-mutant acute leukemias. The company's strategy leverages deep mechanistic insight to target key drivers of oncogenesis and fibrosis, aiming to deliver transformative therapies. With a disciplined approach to clinical development and a strong cash position, Syndax is advancing a targeted pipeline toward key regulatory milestones.
View full company profileTherapeutic Areas
Other Chronic Graft-versus-Host Disease (cGVHD) Drugs
| Drug | Company | Phase |
|---|---|---|
| ROMVIMZA (Vimseltinib) | Deciphera Pharmaceuticals | Phase 2 |